3 Firms Steer $260M Deal For Migraine Drug Royalty Interest
Royalty Pharma said Monday it has agreed to pay $260 million to pick up Arteaus Therapeutics' royalty interest on future sales of a migraine treatment developed by Eli Lilly in a...To view the full article, register now.
Already a subscriber? Click here to view full article